Aligos Therapeutics (NASDAQ:ALGS) Shares Down 6% – Time to Sell?

Aligos Therapeutics, Inc. (NASDAQ:ALGS)’s stock price traded down 6% during mid-day trading on Wednesday . The stock traded as low as $6.81 and last traded at $7.07. 52,875 shares changed hands during mid-day trading, a decline of 33% from the average session volume of 78,377 shares. The stock had previously closed at $7.52.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ALGS shares. Wall Street Zen lowered Aligos Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. UBS Group assumed coverage on shares of Aligos Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $20.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $35.00.

Aligos Therapeutics Price Performance

The business has a 50 day moving average price of $9.46 and a 200 day moving average price of $9.26. The stock has a market capitalization of $43.48 million, a PE ratio of -0.36 and a beta of 2.66.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($3.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.09) by ($0.95). The firm had revenue of $0.74 million during the quarter, compared to the consensus estimate of $0.50 million. Aligos Therapeutics had a negative return on equity of 39.35% and a negative net margin of 3,267.65%. On average, equities analysts expect that Aligos Therapeutics, Inc. will post -10.36 earnings per share for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ALGS. Sio Capital Management LLC lifted its position in Aligos Therapeutics by 85.9% in the 2nd quarter. Sio Capital Management LLC now owns 335,937 shares of the company’s stock valued at $2,422,000 after acquiring an additional 155,217 shares in the last quarter. Woodline Partners LP bought a new stake in shares of Aligos Therapeutics in the 1st quarter worth $2,602,000. Readystate Asset Management LP raised its stake in shares of Aligos Therapeutics by 48.5% in the third quarter. Readystate Asset Management LP now owns 203,113 shares of the company’s stock worth $1,991,000 after purchasing an additional 66,331 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Aligos Therapeutics by 22.8% during the third quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock valued at $1,683,000 after purchasing an additional 31,913 shares in the last quarter. Finally, Two Sigma Investments LP lifted its holdings in shares of Aligos Therapeutics by 223.0% during the third quarter. Two Sigma Investments LP now owns 38,995 shares of the company’s stock valued at $382,000 after purchasing an additional 26,922 shares in the last quarter. 60.43% of the stock is currently owned by hedge funds and other institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.